The Semax Family and Adamax’s Adamantane Modification

Semax is a defined ACTH-fragment analog, while Adamax is a research-market name used for more than one specified structure. PeptidesDirect distinguishes a 984 Da non-adamantane construct from a 1032 Da adamantylglycine construct. The adamantane group creates a chemically distinct molecule, but direct peer-reviewed evidence has not established that it improves Adamax stability, brain exposure, duration or potency.

What belongs to the Semax family?

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its first four residues are derived from ACTH(4-7), while the Pro-Gly-Pro tail is a stabilizing extension. Published Semax studies have examined neurotrophin gene expression and cerebral-ischemia models, mostly in rodents.

A shared MEHFPGP core does not make every derivative equivalent. N-terminal acetylation, C-terminal amidation, sequence extensions and bulky terminal groups change chemical identity and molecular mass. Findings from Semax therefore provide family background, not direct evidence for every modified construct.

Semax, acetylated variants and separate identities

Semax is the parent sequence. N-acetyl Semax adds an acetyl cap at the N-terminus. Semax Amidate changes the C-terminus, and N-Acetyl Semax Amidate combines both terminal modifications. Each is a separate analytical identity and should have its own target sequence, theoretical mass and matching lot data.

The presence of a modification can motivate a stability experiment, but its name does not prove longer persistence, greater brain exposure or stronger biological activity. Those properties require direct, construct-specific studies.

Adamax is not one standardized molecule

Adamax is a research-market name rather than a standardized nonproprietary chemical name. PeptidesDirect lists two different 5mg products under that family name. Their 984 Da and 1032 Da labels are rounded molecular-mass identifiers, not two strengths of one compound.

Adamax 984 Da is specified as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-OH (Ac-MEHFPGPAG-OH), with formula C₄₄H₆₁N₁₁O₁₃S and an average molecular mass near 984.1 Da. It has an Ala-Gly extension and a free-acid C-terminus. Its specified structure contains no adamantane group.

Adamax 1032 Da is specified as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Adamantylglycine-NH₂, with formula C₅₀H₆₉N₁₁O₁₁S and an average molecular mass near 1032.2 Da. It has an N-acetylated Semax-family core and a C-terminal adamantylglycine amide. It is also distinct from N-Acetyl Semax Amidate, which is a separate molecule near 855 Da.

What is the adamantane modification?

Adamantane is a rigid, cage-shaped hydrocarbon. Attaching an adamantane-based group can substantially change a molecule's size, shape and lipophilic character. In Adamax 1032 Da, the specified terminal residue is adamantylglycine and the C-terminus is amidated.

The roughly 48 Da difference between the 984 and 1032 labels is the net difference between two complete specified molecules. It is not the mass of a simple adamantane group added to an otherwise unchanged 984 Da peptide.

Where the Adamax design hypothesis comes from

An adamantylglycine modification was studied in P021, a different peptide derived from a ciliary-neurotrophic-factor sequence. Mouse studies of P021 provide a rationale for asking whether such a terminal group can alter stability or exposure in that molecule.

That rationale cannot be transferred to Adamax as a result. P021 is not Adamax, and Semax studies did not test Adamax 1032 Da. No independent peer-reviewed study directly characterizing or comparing the 984 Da and 1032 Da Adamax constructs was identified for this article.

What the Semax evidence does—and does not—show

Dolotov and colleagues reported changes in BDNF and TrkB expression after Semax exposure in rat hippocampus. Other Semax studies have examined neurotrophin gene expression and ischemia-related molecular responses in animal models. These findings establish research questions for the parent peptide; they do not demonstrate benefits for Adamax.

Claims that Adamax crosses the blood-brain barrier more effectively, lasts longer, is more potent or produces clinical benefits remain unverified for the specified 984 Da and 1032 Da constructs. A plausible design idea is not a measured outcome.

How the two Adamax constructs should be verified

Identity begins with an original construct specification that names the full sequence, terminal modifications, formula and theoretical mass. LC-MS can then test whether the observed intact mass supports that assignment for the matching lot.

Identity, purity and quantity are separate questions. A high HPLC purity result does not establish which Adamax construct is present, and a mass match does not by itself prove that a vial contains 5mg. Reports should identify the lot and state which measurement supports each claim.

Peptide Purity vs Identity vs Content

The defensible research question

Adamax 1032 Da is best treated as a hypothesis to test: does its specified adamantylglycine terminus change measured stability, exposure or model-specific responses compared with confirmed Semax-family comparators? A useful experiment would first verify each construct, then compare them under matched analytical and biological conditions.

Until direct compound-specific data exist, Semax evidence and P021 design work should remain attributed to those molecules. Neither source establishes Adamax performance, safety or therapeutic use.

Evidence guides

How Peptide Lab Verification Works — How HPLC, LC-MS, content testing and lot records fit together.
How to Verify Peptide Authenticity — A checklist for identity, lot matching and report provenance.
How to Choose a Research Peptide Supplier — Evaluate suppliers on specifications, documentation and handling.
Peptide Purity vs Identity vs Content — Why purity, identity and net peptide content are separate measurements.

Frequently asked questions

Is Adamax the same as Semax?

No. Adamax is a research-market family name used for modified Semax-family constructs. Parent-Semax findings provide background but do not establish the behavior of Adamax 984 Da or 1032 Da.

Does Adamax 984 Da contain adamantane?

Not in the specified 984 Da structure. It is listed as Ac-MEHFPGPAG-OH, with an Ala-Gly extension and free-acid C-terminus.

What is modified in Adamax 1032 Da?

The specified 1032 Da construct combines an N-acetylated Semax-family core with a C-terminal adamantylglycine amide. That makes it chemically distinct from Adamax 984 Da and N-Acetyl Semax Amidate.

Does adamantane prove Adamax lasts longer or enters the brain better?

No. An adamantane-based terminal group provides a research hypothesis, not proof. Direct peer-reviewed Adamax pharmacokinetic or brain-exposure studies were not identified.

How can the Adamax constructs be distinguished?

Use a construct specification naming the sequence and modifications, then compare a matching lot's observed LC-MS mass with the theoretical mass. Purity and vial quantity require separate measurements.

References

More peptide science

Research Use Only. Educational laboratory information; not medical advice.